In neuromyelitis optica spectrum disorder (NMOSD), enhanced plasma cell activity contributes to antiaquaporin-4 autoantibody (AQP4-ab) production. 1 Longitudinal data indicate that 25% to 66% of patients with NMOSD who are treated with azathioprine, rituximab, and other immune-modifying therapies still experience relapses. 2 Here we assess the safety and efficacy of bortezomib, a selective inhibitor of the 26S proteasome subunit, among patients with highly relapsing NMOSD.
per cycle followed by a 10-day treatment-free interval. This intervention was concurrent with an oral corticosteroid or azathioprine regimen.
Relapses, Expanded Disability Status Scale scores, and pain levels (visual analog scale) were assessed by 2 experienced neurologists who were blinded to the study. Serum AQP4-ab titers were tested by a green fluorescent protein-AQP4 fluorescence immunoprecipitation assay. Peripheral B cells and plasma cell counts were measured by flow cytometry with anticluster of differentiation (CD) 19 (allophycocyanin; Biolegend) and anti-CD138 (fluorescein isothiocyanate; Biolegend), respectively. Descriptive values are given as medians (interquartile range [IQR] ) for continuous variables.
Results | Despite undergoing vigorous therapies (Table) , all the patients experienced at least 2 relapses in the previous 6 months or 3 relapses throughout the years (Figure, A) . After initiating bortezomib treatment, 4 of the 5 patients, including patient 2, were relapse-free during the 1-year follow-up. A myelitis relapse was only observed in patient 1 when the patient experienced slight paraplegia 10 months following the onset of bortezomib. Magnetic resonance imaging with gadolinium enhancement showed a new lesion in the 12th thoracicfirst lumbar segment of the spinal cord. Prompt treatment with intravenous methylprednisolone (500 mg/d) for 5 days ameliorated her symptoms.
None of the 5 patients experienced further neurological deterioration at the conclusion of the study. The median Expanded Disability Status Scale scores reduced from a median (IQR) of 5. 50 (3.75-6.25 ) at baseline to 3.50 (0.75-4.25) after 1-year follow-up (Figure, B) . Their visual analog scale scores also declined from a median (IQR) of 6.0 (5.0-6.75) on study entry to 3.0 (2.25-3.75) after 12 months. Compared with the baseline, serum AQP4-ab titers reduced from a median (IQR) of 66.4nM (35.7-147.3) to 27.1nM (18.7-34.9 ) after 1 year (median reduction, 59.2%) (Figure, C) . Peripheral CD19 + B cell counts declined from a median (IQR) of 230/μL (175-390) to 41/μL (21-158) and CD138 + plasma cell counts decreased from 7/μL (6-13) to 2/μL (1-3) after 1 year. Finally, the observed adverse effects related to bortezomib were mild and transient (Table) . a The patient had ever received rituximab treatment, total 400 mg/cycle, 2 cycles to ensure that CD19 + and CD27 + memory B cells were less than 0.05% of the peripheral blood mononuclear cell count. b The reason for discontinuation of AZA treatment was hepatic dysfunction.
c Before receiving a bortezomib infusion, the peripheral blood CD19 + B cells counts of all the 5 patients were in the normal range. 
COMMENT & RESPONSE

Confusing Terminology-Neuroleptic Malignant Syndrome vs Malignant Hyperthermia
To the Editor I would like to point out an error in the otherwise excellent review by Damier and Al-Hashel. 1 The authors state that a "sudden withdrawal of dopamine replacement drugs is associated with the risk of a life-threatening malignant hyperthermia syndrome" and reference a case report of neuroleptic malignant syndrome that occurred on withdrawal of levodopa therapy.
2 Because the names of the 2 syndromes are similar, these disorders are commonly confused. Neuroleptic malignant syndrome is a clinical syndrome characterized by mental status changes, generalized rigidity, fever, and dysautonomia The arrowheads indicate the treatment option in acute relapse. After receiving 4 cycles of BTZ treatment, all patients continued to receive the treatment of oral prednisone or azathioprine. IV indicates intravenous. Alteration of Expanded Disability Status Scale (EDSS) scores (B) and serum antiaquaporin-4 autoantibody (AQP4-ab) titers (C) among patients with neuromyelitis optica spectrum disorder receiving BTZ treatment during 1-year follow up. The 0 month represents baseline before BTZ was administered. The cutoff of the negative value of the AQP4-antibody, shown by the dotted line, was set at 15.0nM in serum.
